DISEASE & TREATMENT SETTING

Acute Myeloid Leukemia

Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.

Exact scope

Treatment of Untreated Acute Myeloid Leukemia

Broader topic: Acute Myeloid Leukemia

Source population: Not part of this definition
Disease extent: Not part of this definition
Treatment line: Not part of this definition
Stage: Not part of this definition
Resectability: Not part of this definition

Biomarkers, prior therapy and derivation

molecular

prior therapy

class
no prior therapy
status
stated

derivation status

source-attested

derivation note

Scoped from an NCI treatment-summary heading. NCI PDQ is an evidence summary, not a practice guideline, and only the dimensions the heading states are part of this definition.

source wording

Treatment of Untreated Acute Myeloid Leukemia

Study evidence for this setting

Find a linked studyHow it was found

0 linked studies · Applicability is a draft source assessment, not a determination of your eligibility.

No linked study matches these filters. This is a source-coverage gap, not evidence that there are no treatment options.

Indication-specific source history

Dated source events, not confirmation of current approval for every use of a drug.

2025-01-21 · treosulfan with fludarabine · approval notification

release id: clinical-indications-draft-1
disease state id: ds-acute-myeloid-leukemia-scoped-946f2625
event id: notice-8167557c081fa8b8
event date: 2025-01-21
event kind: approval-notification
drug or regimen: treosulfan with fludarabine
source indication text: FDA approved treosulfan, an alkylating agent, with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation in adult and pediatric patients 1 year of age and older with acute myeloid leukemia or myelodysplastic syndrome .
match phrase: acute myeloid leukemia
match status: candidate
status category: Source null
has date discrepancy: 0
source collection: fda-approval-notice
source key: fda-eed3ef224dcd705a
source url: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-treosulfan-fludarabine-preparative-regimen-allohsct-adult-and-pediatric-patients-aml-or
curation status: draft
reviewed by: Source null
reviewed at: Source null
created at: 2026-09-10T00:00:00Z

Original event source →

2025-10-24 · revumenib · approval notification

release id: clinical-indications-draft-1
disease state id: ds-acute-myeloid-leukemia-scoped-946f2625
event id: notice-4f40a0888c5559f9
event date: 2025-10-24
event kind: approval-notification
drug or regimen: revumenib
source indication text: FDA approved revumenib, a menin inhibitor, for relapsed or refractory acute myeloid leukemia with a susceptible nucleophosmin 1 mutation in adult and pediatric patients 1 year and older who have no satisfactory alternative treatment options.
match phrase: acute myeloid leukemia
match status: candidate
status category: Source null
has date discrepancy: 0
source collection: fda-approval-notice
source key: fda-61ed478e73d4f4a0
source url: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-revumenib-relapsed-or-refractory-acute-myeloid-leukemia-susceptible-npm1-mutation
curation status: draft
reviewed by: Source null
reviewed at: Source null
created at: 2026-09-10T00:00:00Z

Original event source →

2025-11-13 · ziftomenib · approval notification

release id: clinical-indications-draft-1
disease state id: ds-acute-myeloid-leukemia-scoped-946f2625
event id: notice-5cc5182be0748947
event date: 2025-11-13
event kind: approval-notification
drug or regimen: ziftomenib
source indication text: FDA approved ziftomenib, a menin inhibitor, for adults with relapsed or refractory acute myeloid leukemia with a susceptible nucleophosmin 1 mutation who have no satisfactory alternative treatment options.
match phrase: acute myeloid leukemia
match status: candidate
status category: Source null
has date discrepancy: 0
source collection: fda-approval-notice
source key: fda-970653d3c34dd8d5
source url: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-ziftomenib-relapsed-or-refractory-acute-myeloid-leukemia-npm1-mutation
curation status: draft
reviewed by: Source null
reviewed at: Source null
created at: 2026-09-10T00:00:00Z

Original event source →

2026-05-13 · oral combination of decitabine and cedazuridine tablets with venetoclax · approval notification

release id: clinical-indications-draft-1
disease state id: ds-acute-myeloid-leukemia-scoped-946f2625
event id: notice-000b45c7dad0c1d7
event date: 2026-05-13
event kind: approval-notification
drug or regimen: oral combination of decitabine and cedazuridine tablets with venetoclax
source indication text: FDA approved an oral combination of decitabine and cedazuridine tablets with venetoclax for the treatment of newly diagnosed acute myeloid leukemia in adults 75 years or older, or who have comorbidities that preclude the use of intensive induction chemotherapy.
match phrase: acute myeloid leukemia
match status: candidate
status category: Source null
has date discrepancy: 0
source collection: fda-approval-notice
source key: fda-990c1df07ad6d6a2
source url: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-oral-combination-decitabine-and-cedazuridine-tablets-venetoclax-newly-diagnosed-acute
curation status: draft
reviewed by: Source null
reviewed at: Source null
created at: 2026-09-10T00:00:00Z

Original event source →

Source relationships and population-mapping limitations

bindings
mappings

Download this complete draft source relationship record →

Preserved source evidence · Not medical advice